#Japan #Hiroshima #Ractigen Therapeutics #Duchenne Muscular Dystrophy #RNA Activation

Ractigen Therapeutics to Present Promising RNA Activation Data in Duchenne Muscular Dystrophy

Ractigen Therapeutics, a forward-thinking biotechnology firm focused on RNA activation (RNAa) therapeutics, is set to make a significant impact at the upcoming 31st Annual Congress of the World Muscle Society (WMS 2026), scheduled from September 29 to October 3 in Hiroshima, Japan. The company has announced that its first-in-human findings from the RAG-18 program, aimed at treating Duchenne muscular dystrophy (DMD), will be showcased in a Late-Breaking Presentation.

The prestigious Late-Breaking designation is awarded to research the program committee recognizes as timely and highly relevant. The findings shared by Ractigen are anticipated to provide critical clinical evidence demonstrating how a small activating RNA (saRNA) can enhance the production of an endogenous target protein in patients suffering from this monogenic disorder. Notably, the activation of utrophin, a protein similar to dystrophin, could offer a mutation-independent strategy relevant to a wide array of DMD genotypes.

Significance of Utrophin in DMD Treatment

For over two decades, the neuromuscular research community has identified utrophin as a compelling therapeutic target in the treatment of DMD. Unlike dystrophin, whose absence is responsible for the progression of this devastating disease, utrophin can serve as a substitute at the muscle membrane irrespective of the specific DMD mutation. Therefore, a method to effectively increase utrophin levels in patients, using an innovative RNA-based technology, could revolutionize DMD treatment.

Presentation Details and Insights

The upcoming presentation, titled "First-in-human evidence of RNA activation-mediated sarcolemmal utrophin upregulation in Duchenne muscular dystrophy," will be delivered by Professor Yi Dai, MD, PhD, from the Peking Union Medical College Hospital. The discussions will include preliminary results from the ongoing, open-label, dose-escalation clinical trial (NCT07282652), which focuses on ambulatory boys with genetically confirmed DMD.

Data to be shared will encompass several critical aspects, including safety and tolerability assessments, muscle biopsy results via quantitative immunofluorescence, muscle histopathology evaluations, serum creatine kinase levels, quantitative muscle MRI assessments, spirometry, and motor function evaluations. Professor Dai commented on the potential of this new therapeutic avenue, emphasizing the necessity for therapies that are effective across the diverse mutation spectrum seen in DMD patients.

Future Implications for RNA Activation and DMD

Long-Cheng Li, the CEO of Ractigen Therapeutics, highlighted the significance of this late-breaking presentation, describing it as a pivotal moment not only for Ractigen but for the entire RNA therapeutic field. He noted that RNA activation has long been viewed as a promising concept; however, the recent findings indicate that saRNA can successfully activate gene expression in human skeletal muscle, thereby restoring cellular integrity. The implications of RAG-18 extend beyond just DMD treatment, as the results could influence future RNA-based therapies for various genetic disorders.

Additional Context on Duchenne Muscular Dystrophy

DMD is a rare and severe neuromuscular disorder predominantly affecting boys, caused by mutations in the DMD gene, leading to a deficiency in dystrophin. This condition is characterized by muscular degeneration, loss of mobility, respiratory difficulties, and cardiac problems. By increasing endogenous utrophin levels, a theoretically effective treatment could apply to all patients regardless of their specific genetic mutation.

Conclusion

Ractigen Therapeutics' participation in the WMS 2026 is not just a presentation of data but an opportunity to engage the global neuromuscular community in a conversation about groundbreaking advancements in RNA therapies. As the event approaches, the anticipation grows for what could be a monumental leap in treating Duchenne muscular dystrophy and improving patients' lives. In compliance with WMS regulations, more detailed quantitative datasets and comprehensive clinical outcomes will be disclosed during the formal oral presentation, emphasizing the potential of RNA activation in transformative healthcare solutions.

For those interested in following the developments in this groundbreaking research, more information will be available on the Ractigen website and their official social media channels as the presentation date approaches.